A Quantitative Proteomic Study of Tolvaptan Treatment in an Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease: What Remains Altered?

被引：0
|
作者：
Nunez-Gonzalez, Laura [6 ]
Cordido, Adrian [1 ,6 ]
Vizoso, Marta [1 ]
Gomez Garcia, Fernando [1 ]
Bravo, Susana [3 ]
Rodriguez, Candido D. [1 ,5 ]
Ortiz, Alberto [2 ]
Garcia-Gonzalez, Miguel A. [1 ,4 ]
机构：
[1] Santiago de Compostela Clin Hosp Complex CHUS, Genet & Dev Biol Kidney Dis, Hlth Res Inst Santiago de Compostela IDIS, Santiago De Compostela, Spain
[2] Univ Madrid UAM, Jimenez Diaz Fdn, Sch Med, Madrid, Spain
[3] Santiago de Compostela Clin Hosp Complex CHUS, Prote Platform Hlth Res Inst Santiago de Composte, Santiago De Compostela, Spain
[4] Santiago de Compostela Clin Hosp Complex CHUS, Galician Publ Fdn Genom Med, Santiago De Compostela, Spain
[5] Santiago de Compostela Clin Hosp Complex, Nephrol Serv, Santiago De Compostela, Spain
[6] Yale Sch Med, Dept Internal Med, New Haven, CT USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2022年 / 33卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
FR-PO273
引用
收藏
页码：400 / 400
页数：1
相关论文
共 50 条
  • [1] Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease
    Vicente E Torres
    Xiaofang Wang
    Qi Qian
    Stefan Somlo
    Peter C Harris
    Vincent H Gattone
    Nature Medicine, 2004, 10 : 363 - 364
  • [2] Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease
    Torres, VE
    Wang, XF
    Qian, Q
    Somlo, S
    Harris, PC
    Gattone, VH
    NATURE MEDICINE, 2004, 10 (04) : 363 - 364
  • [3] Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
    Jouret, Francois
    Krzesinski, Jean-Marie
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (13): : 1258 - 1259
  • [4] Tolvaptan and Autosomal Dominant Polycystic Kidney Disease
    Ingelfinger, Julie R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20): : 1988 - 1989
  • [5] Fatty Acid Oxidation is Impaired in An Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease
    Menezes, Luis F.
    Lin, Cheng-Chao
    Zhou, Fang
    Germino, Gregory G.
    EBIOMEDICINE, 2016, 5 : 183 - 192
  • [6] THE BURDEN OF TOLVAPTAN TREATMENT FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
    Muto, Satoru
    Kawano, Haruna
    Sugiura, Syou-ichiro
    Kitamura, Kousuke
    Kimura, Masaki
    Isotani, Shuji
    Ide, Hisamitsu
    Yamaguchi, Raizo
    Horie, Shigeo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [7] Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Reply
    Torres, Vicente E.
    Gansevoort, Ron T.
    Czerwiec, Frank S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (13): : 1259 - 1259
  • [8] Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease
    Zafar, Iram
    Ravichandran, Kameswaran
    Belibi, Franck A.
    Doctor, R. Brian
    Edelstein, Charles L.
    KIDNEY INTERNATIONAL, 2010, 78 (08) : 754 - 761
  • [9] Review of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
    Baur, Brian P.
    Meaney, Calvin J.
    PHARMACOTHERAPY, 2014, 34 (06): : 605 - 616
  • [10] Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease
    Blair, Hannah A.
    DRUGS, 2019, 79 (03) : 303 - 313
12345